Abstract: This invention relates to local epidural or intraspinal use of compounds of the formula: ##STR1## where X is H or CH.sub.3 and R.sub.1 and R.sub.2, which can be the same or different, are each H or CH.sub.3 and their stereoisomers and their non-toxic, pharmaceutically acceptable salts. Especially useful are the compounds known under the generic names medetomidine ((.+-.)-4-[1-(2,3-dimethylphenyl)ethyl]-1H-imidazole), dexmedetomidine (+)-4-[1-(2,3-dimethylphenyl)ethyl]-1H-imidazole and detomidine 4-(2,3-dimethylbenzyl)-1H-imidazole.

Abstract: A preventive and therapeutic agent for hepatitis, comprising a fat emulsion containing a compound having prostaglandin E.sub.1 activities.

Abstract: The use of cyclocreatine to preserve and/or restore the physiological functionality of muscle tissue subject to ischemia.

Abstract: A method for the prevention of central nervous system toxicity of acivicin which comprises the concomitant administration of acivicin and an amino acid solution consisting essentially of large neutral amino acids.

Abstract: The invention concerns compounds having formula: ##STR1## or a salt thereof, wherein E represents hydrogen, lower alkyl or a group Ar.sup.1 --A.sup.1 ; Ar and Ar.sup.1 are the same or different aryl groups (including heteroaryl) which are optionally substituted, e.g. by one or more substituents commonly used in pharmaceutical chemistry; A and A.sup.1 are the same or different alkylene groups having one or two carbon atoms linking Ar or Ar.sup.1 to N and optionally substituted by lower alkyl and/or optionally substituted aryl, B is an alkylene group of 3 or 4 carbon atoms, which may be substituted by lower alkyl; D.sup.1 represents halogen, CH.sub.3, CR.sup.1 R.sup.2 NH.sub.2, SO.sub.3 H or SO.sub.2 NR.sup.6 R.sup.7 where R.sup.1 and R.sup.2 are independently hydrogen or lower alkyl and R.sup.6 and R.sup.7 are each hydrogen, lower alkyl or aralkyl of 7 to 12 carbon atoms or R.sup.6 and R.sup.

Abstract: This invention provides 3-quinuclidinyl benzamides which in the form of pharmaceutical compositions have utility as therapeutic agents which exhibit anxiolytic antipsychotic and cognitive improving effects in warm blooded animals.Illustrative of an invention compound is N-(1-azabicyclo[2.2.2]oct-3-yl)-5-chloro-4-dimethylamino-2-hydroxythiobenz amide: ##STR1## or a pharmaceutically acceptable salt thereof.

Abstract: The present invention relates to a method for preventing or treating renal failure in a mannal which comprises administering the mammal an effective amount for renal failure of at least one hydantoin derivative of the following formula (I) or a pharmaeutically acceptable salt thereof.

Abstract: The instant invention is novel uses of known cyclic amino acids. Such compounds as gabapentin are used for treating neurodegenerative disorders, perinatal asphyxia, status epilepticus, Alzheimer's Hungington's, Parkinson's, and Amyotrophic Lateral Sclerosis.

Abstract: A novel method for the prevention and control of epileptic seizures particulary in patients with uncontrolled complex partial seizures employing pharmaceutical compositions containing 2-phenyl-1,3-propanediol dicarbamate.

Abstract: A method for moderating the rate of cellular mitosis in a living mammalian tissue having a pathologically elevated rate of cellular mitosis sensitive to treatment with a solution below which comprises perfusing said tissue under mitotic growth conditions with a safe and effective amount and concentration of a composition consisting essentially of a) inositol hexaphosphate or a physiologically acceptable salt thereof; and b) a source of inositol or a physiologically acceptable salt thereof, for a period of time sufficient to moderate the elevated rate of cellular mitosis to a normal, non-pathological rate for said tissue. The method is useful in human and mammalian diseases wherein NK cell activity is altered in the laboratory, e.g. tumors, other cancers including leukemia, immunosuppressed individuals (AIDS and transplant recipients), and in viral, fungal or protozoal infections.

Abstract: The invention discloses the use of the R-(+)-isomer of 2-methoxy-3-octadecyloxy-propanol-(1)-phosphoric acid, monocholine ester in treating multiple sclerosis and to pharmaceutical compositions containing said isomer.

Abstract: Disclosed are stabilized aqueous preparations containing an antidepressant in admixture with a stabilizing compound such as L-methionine, D-methionine, DL-methionine, or mixtures thereof. The stabilized preparations display better stability when exposed to light, relatively high temperatures, time, and peroxides resulting in longer shelf-lives. Antidepressants which are stabilized include mirtazapine, mianserin, septiline, and amitriptyline.

Abstract: Disclosed herein are anti-inflammatory and anti-ulcer copper coordination compounds and a process for using them in the treatment of arthritis and gastrointestinal ulcers in animal bodies. The copper coordination compounds utilized are the reaction products of copper salts with:1. aromatic carboxylic acids or their alkaline earth salts;2. heterocyclic carboxylic acids or their alkaline earth salts;3. amino acids or their alkaline earth salts;4. amines; and5. suitably substituted steroids.The process disclosed comprises administering to experimental animals, orally or parentrally (subcutaneously), in controlled dosages, the aforementioned copper coordination compounds for the treatment of inflammation (i.e., arthritis) and ulcers of the gastrointestinal tract.

Abstract: The present invention is directed to a method of stimulating superoxide generation using phenolic thioethers which stimulate the generation of superoxide.

Abstract: The anti-viral effectiveness of conventional anti-viral agents such as acyclovir, idoxuridine, vidarabine etc. is enhanced by formulation or administration with a physiologically acceptable lithium salt.

Abstract: Compounds useful for the treatment of patients suffering from muscle spasms of the formula (I) ##STR1## in which R represents the radical ##STR2## in which R.sub.1, in any position on the phenyl nucleus, represents a linear, branched or cyclic alkyl, alkenyl or alkynyl, containing up to 8 carbon atoms, or the radical ##STR3## in which R.sub.2 and R.sub.3, identical or different each represents a hydrogen atom, a linear alkyl, alkenyl or alkynyl, containing up to 8 carbon atoms, or form together with the nitogen atom to which they are joined, a heterocyclic radical optionally containing another heteroatom, or NO.sub.2, or OR', R' representing hydrogen, a linear, branched or cyclic alkyl containing up to 8 carbon atoms, or aryl containing up to 14 carbon atoms, or an SR.sub.4 or S(O)R.sub.5 radical, R.sub.4 and R.sub.5 representing a linear, branched or cyclic alkyl, alkenyl or alkynyl, containing up to 8 carbon atoms, or R represents naphthyl, optionally substituted by an R.sub.

Abstract: Treatment of patients suffering from anemias such as anemias of chronic disorders or anemias resulting as toxic side effects of drugs, ionizing radiation or kidney dialysis by administration of a serotonin antagonist, such as cyproheptadine, the administration taking place once a day during the evening, preferably after sunset.

Abstract: The invention relates to a therapeutical composition of matter for the treatment by perfusion of shock states comprising as an essential ingredient therein, an effective amount either, of a compound of the formula: ##STR1## wherein R.sub.1 and R.sub.4 stant for H or CH.sub.3 or C.sub.2 H.sub.5,R.sub.2 stands for H or NO.sub.2 andR.sub.3 stands for NHR.sub.4 or CH.sub.3 or C.sub.2 H.sub.5alone or of a mixture of said compound with a cyclooxygenase blocker.

Abstract: The present invention relates to a useful antihepatopathic composition comprising a compound of the formula: ##STR1## (wherein the R groups are the same or different and each means a hydrogen atom or a lower alkyl group) or a pharmaceutically acceptable salt thereof as an active ingredient.

Abstract: The invention relates to the use of 5-alkylpyridazine derivatives of the formula ##STR1## in which R.sub.1 is a C.sub.1 -C.sub.4 alkyl group or a phenyl group and R.sub.2 and R.sub.3 independently are a C.sub.1 -C.sub.4 alkyl group, or R.sub.2 and R.sub.3, taken with the nitrogen atom to which they are bonded, form a morpholino group, or one of their pharmaceutically acceptable salts, for the preparation of pharmaceutical compositions for combating pathological conditions associated with a cortical cholinergic deficiency, especially for the treatment of degenerative syndromes associated with senescence.